Here are four observations:
1. In 2015, the market was valued at $160 million.
2. The market is expected to be worth $451.9 million by 2024.
3. The pure-platelet rich plasma segment accounted for more than 60 percent of the market.
4. Key market players include:
• AdiStem in Australia
• Arthrex in Naples, Fla.
• Zimmer Biomet in Warsaw, Ind.
• Cesca Therapeutics in Rancho Cordova, Calif.
• DePuy Synthes in West Chester, Pa.
• EmCyte Corp. in Fort Myers, Fla.
• Exactech in Gainesville, Fla.
• Harvest Technologies Corp. in Plymouth, Mass.
• Nuo Therapeutics in Gaithersburg, Md.
• Regen Lab in Le Mont-sur-Lausanne, Switzerland
• Stryker Corp. in Kalamazoo, Mich.
More articles on spine:
Dr. Patrick Senatus induced into International Association of HealthCare Professionals: 5 things to know
SCS therapy declines or stabilizes opioid usage: 4 insights
5 things to know about gunshot-induced spinal cord injury: Is surgery overused?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.